NCT02394535 - Nab-Paclitaxel, Capecitabine, and Radiation Therapy Following Induction Chemotherapy in Treating Patients With Locally Advanced Pancreatic Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 12, 2015

Primary Completion Date

August 31, 2022

Study Completion Date

August 31, 2022

Conditions

Borderline Resectable Pancreatic AdenocarcinomaLocally Advanced Pancreatic AdenocarcinomaPancreatic AdenocarcinomaStage II Pancreatic Cancer AJCC v6 and v7Stage IIA Pancreatic Cancer AJCC v6 and v7Stage IIB Pancreatic Cancer AJCC v6 and v7Stage III Pancreatic Cancer AJCC v6 and v7

Interventions

DRUG

Capecitabine

Given PO

OTHER

Laboratory Biomarker Analysis

Correlative studies

DRUG

Nab-paclitaxel

Given IV

OTHER

Questionnaire Administration

Ancillary studies

RADIATION

Radiation Therapy

Undergo radiation therapy

Trial Locations (5)

77030

M D Anderson Cancer Center, Houston

77094

MD Anderson in Katy, Houston

77384

MD Anderson in The Woodlands, The Woodlands

77478

MD Anderson in Sugar Land, Sugar Land

77573

MD Anderson Cancer Center - League City, League City

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER